Targeting Sialylation Enhances the Therapeutic Efficacy of the Nectin-4–Targeted Antibody–Drug Conjugate Enfortumab Vedotin in Bladder Cancer
Suppressed enfortumab vedotin endocytosis and elevated degradation of its target Nectin-4 is mediated by sialylation, which can be targeted to improve the therapeutic efficacy of the antibody-drug conjugate in bladder cancer.
Authors
- Ming Huang (ORCID: https://orcid.org/0009-0006-0248-408X)
- Yuxuan Song (ORCID: https://orcid.org/0000-0001-8326-0948)
- Caipeng Qin
- Xing Luo (ORCID: https://orcid.org/0000-0003-3178-877X)
- Tao Xu (ORCID: https://orcid.org/0000-0003-3899-1500)
- Jilin Wu (ORCID: https://orcid.org/0000-0003-1489-1441)
- Yiqing Du (ORCID: https://orcid.org/0000-0002-5089-727X)
- Bisheng Cheng (ORCID: https://orcid.org/0000-0002-6114-6623)
- Gao Hui-bin (ORCID: https://orcid.org/0009-0000-4191-080X)
- Fei Wang (ORCID: https://orcid.org/0000-0001-9481-0909)
- Jue Cheng (ORCID: https://orcid.org/0009-0004-6105-5125)
Institutions
- Sun Yat-sen University (CN)
- Peking University (CN)
- Beijing Jishuitan Hospital (CN)
- Sun Yat-sen Memorial Hospital (CN)
- Peking University People's Hospital (CN)
- Southern Medical University (CN)
Publication Details
- Journal
- Cancer Research
- Published
- 2025-10-09
- DOI
- https://doi.org/10.1158/0008-5472.can-25-0024
- Citations
- 2
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 4.01